REGENXBIO Inc. (NASDAQ:RGNX) Receives Consensus Rating of "Moderate Buy" from Analysts

REGENXBIO Inc. (NASDAQ:RGNX - Get Free Report) has earned an average recommendation of "Moderate Buy" from the twelve analysts that are covering the company, Marketbeat reports. One analyst has rated the stock with a hold recommendation and eleven have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $34.82.

A number of brokerages have issued reports on RGNX. HC Wainwright reissued a "buy" rating and issued a $36.00 target price on shares of REGENXBIO in a research report on Wednesday, January 15th. Raymond James reiterated an "outperform" rating and issued a $18.00 price objective on shares of REGENXBIO in a report on Thursday, October 10th. Chardan Capital restated a "buy" rating and set a $52.00 target price on shares of REGENXBIO in a report on Wednesday, November 20th. Morgan Stanley reaffirmed an "overweight" rating and issued a $22.00 target price on shares of REGENXBIO in a research report on Friday, November 15th. Finally, Royal Bank of Canada restated an "outperform" rating and issued a $30.00 price objective on shares of REGENXBIO in a report on Tuesday, January 21st.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of RGNX. FMR LLC lifted its holdings in REGENXBIO by 166.8% in the 3rd quarter. FMR LLC now owns 2,649 shares of the biotechnology company's stock valued at $28,000 after purchasing an additional 1,656 shares in the last quarter. nVerses Capital LLC lifted its stake in shares of REGENXBIO by 183.3% during the third quarter. nVerses Capital LLC now owns 3,400 shares of the biotechnology company's stock valued at $36,000 after buying an additional 2,200 shares during the period. GAMMA Investing LLC boosted its position in REGENXBIO by 273.1% during the fourth quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company's stock worth $27,000 after acquiring an additional 2,510 shares during the last quarter. The Manufacturers Life Insurance Company grew its stake in REGENXBIO by 19.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,375 shares of the biotechnology company's stock worth $215,000 after acquiring an additional 3,015 shares during the period. Finally, China Universal Asset Management Co. Ltd. lifted its stake in shares of REGENXBIO by 64.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,506 shares of the biotechnology company's stock worth $100,000 after purchasing an additional 3,720 shares during the period. 88.08% of the stock is currently owned by institutional investors and hedge funds.

REGENXBIO Price Performance

RGNX traded down $0.25 during trading hours on Friday, reaching $7.82. The company's stock had a trading volume of 1,022,013 shares, compared to its average volume of 1,134,160. The business's 50-day moving average is $8.23 and its 200-day moving average is $10.19. The stock has a market cap of $387.40 million, a PE ratio of -1.55 and a beta of 1.29. REGENXBIO has a fifty-two week low of $6.56 and a fifty-two week high of $28.80.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.